S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69

Surgery Partners Stock Forecast, Price & News

-2.77 (-6.17%)
(As of 01/21/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
291,181 shs
Average Volume
408,570 shs
Market Capitalization
$3.76 billion
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive SGRY News and Ratings via Email

Sign-up to receive the latest news and ratings for Surgery Partners and its competitors with MarketBeat's FREE daily newsletter.

Surgery Partners logo

About Surgery Partners

Surgery Partners, Inc. is healthcare services holding company, which engages in the provision of solutions for surgical and related ancillary care in support of its patients and physicians. It operates through the following business segments: Surgical Facility Services, Ancillary Services, and Optical Services. The Surgical Facility Services segment consists of the operation of ambulatory surgery centers and surgical hospitals, including anesthesia services of the company. The Ancillary Services segment operates a diagnostic laboratory and multi-specialty physician practices. The Optical Services segment involves an optical laboratory and an optical products group purchasing organization. The company was founded in 2004 and is headquartered in Brentwood, TN.


See More Headlines

Industry, Sector and Symbol

General medical & surgical hospitals
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$1.86 billion
Cash Flow
$1.08 per share
Book Value
$17.48 per share


Net Income
$-116.10 million
Pretax Margin




Free Float
Market Cap
$3.76 billion

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

1.59 out of 5 stars

Medical Sector

1044th out of 1,418 stocks

General Medical & Surgical Hospitals Industry

5th out of 7 stocks

Analyst Opinion: 3.3Community Rank: 4.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Surgery Partners (NASDAQ:SGRY) Frequently Asked Questions

Is Surgery Partners a buy right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Surgery Partners in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Surgery Partners stock.
View analyst ratings for Surgery Partners
or view top-rated stocks.

How has Surgery Partners' stock price been impacted by Coronavirus (COVID-19)?

Surgery Partners' stock was trading at $8.86 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, SGRY stock has increased by 375.1% and is now trading at $42.09.
View which stocks have been most impacted by COVID-19

Are investors shorting Surgery Partners?

Surgery Partners saw a increase in short interest in December. As of December 31st, there was short interest totaling 1,760,000 shares, an increase of 17.3% from the December 15th total of 1,500,000 shares. Based on an average daily volume of 382,400 shares, the short-interest ratio is presently 4.6 days. Approximately 4.6% of the company's stock are short sold.
View Surgery Partners' Short Interest

When is Surgery Partners' next earnings date?

Surgery Partners is scheduled to release its next quarterly earnings announcement on Wednesday, March 9th 2022.
View our earnings forecast for Surgery Partners

How were Surgery Partners' earnings last quarter?

Surgery Partners, Inc. (NASDAQ:SGRY) announced its earnings results on Tuesday, November, 2nd. The company reported ($0.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.09) by $0.04. The business earned $559.20 million during the quarter, compared to analysts' expectations of $554.15 million. Surgery Partners had a negative trailing twelve-month return on equity of 0.81% and a negative net margin of 3.02%. During the same quarter last year, the firm earned ($0.59) earnings per share.
View Surgery Partners' earnings history

What guidance has Surgery Partners issued on next quarter's earnings?

Surgery Partners updated its FY 2021 earnings guidance on Tuesday, November, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $2.21 billion-$2.25 billion, compared to the consensus revenue estimate of $2.22 billion.

What price target have analysts set for SGRY?

6 brokerages have issued 1-year target prices for Surgery Partners' shares. Their forecasts range from $50.00 to $73.00. On average, they anticipate Surgery Partners' stock price to reach $57.67 in the next twelve months. This suggests a possible upside of 37.0% from the stock's current price.
View analysts' price targets for Surgery Partners
or view top-rated stocks among Wall Street analysts.

Who are Surgery Partners' key executives?

Surgery Partners' management team includes the following people:
  • J. Eric Evans, Chief Executive Officer & Director
  • Thomas F. Cowhey, CFO, Principal Accounting Officer & Executive VP
  • Varun Gadhok, Chief Information Officer & Senior Vice President
  • Roxanne Womack, Chief Compliance Officer & Senior Vice President
  • Jennifer B. Baldock, Secretary, Chief Administrative Officer & EVP (LinkedIn Profile)

What is Eric Evans' approval rating as Surgery Partners' CEO?

7 employees have rated Surgery Partners CEO Eric Evans on Glassdoor.com. Eric Evans has an approval rating of 86% among Surgery Partners' employees.

What other stocks do shareholders of Surgery Partners own?

What is Surgery Partners' stock symbol?

Surgery Partners trades on the NASDAQ under the ticker symbol "SGRY."

Who are Surgery Partners' major shareholders?

Surgery Partners' stock is owned by many different institutional and retail investors. Top institutional investors include Foster Victor Wealth Advisors LLC (0.01%) and Cutler Group LP (0.00%). Company insiders that own Surgery Partners stock include Anthony Taparo, George Goodwin, Jennifer Baldock, Laura L Brocklehurst, Laura L Brocklehurst, Teresa Deluca and Thomas F Cowhey.
View institutional ownership trends for Surgery Partners

Which major investors are selling Surgery Partners stock?

SGRY stock was sold by a variety of institutional investors in the last quarter, including Cutler Group LP. Company insiders that have sold Surgery Partners company stock in the last year include Anthony Taparo, George Goodwin, Jennifer Baldock, Laura L Brocklehurst, Teresa Deluca, and Thomas F Cowhey.
View insider buying and selling activity for Surgery Partners
or view top insider-selling stocks.

Which major investors are buying Surgery Partners stock?

SGRY stock was purchased by a variety of institutional investors in the last quarter, including Foster Victor Wealth Advisors LLC.
View insider buying and selling activity for Surgery Partners
or or view top insider-buying stocks.

How do I buy shares of Surgery Partners?

Shares of SGRY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Surgery Partners' stock price today?

One share of SGRY stock can currently be purchased for approximately $42.09.

How much money does Surgery Partners make?

Surgery Partners has a market capitalization of $3.76 billion and generates $1.86 billion in revenue each year. The company earns $-116.10 million in net income (profit) each year or ($1.34) on an earnings per share basis.

How many employees does Surgery Partners have?

Surgery Partners employs 10,800 workers across the globe.

What is Surgery Partners' official website?

The official website for Surgery Partners is www.surgerypartners.com.

Where are Surgery Partners' headquarters?

Surgery Partners is headquartered at 310 Seven Springs Way Suite 500, Brentwood TN, 37027.

How can I contact Surgery Partners?

Surgery Partners' mailing address is 310 Seven Springs Way Suite 500, Brentwood TN, 37027. The company can be reached via phone at (615) 234-5900, via email at [email protected], or via fax at 615-234-5998.

This page was last updated on 1/23/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.